Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Empagliflozin/linagliptin

Various toxicities: 7 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Inagaki N, et al. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study. Expert Opinion on Drug Safety 22: 153-163, No. 2, 2023. Available from: URL: https://www.tandfonline.com/loi/ieds20 Inagaki N, et al. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study. Expert Opinion on Drug Safety 22: 153-163, No. 2, 2023. Available from: URL: https://​www.​tandfonline.​com/​loi/​ieds20
Metadaten
Titel
Empagliflozin/linagliptin
Various toxicities: 7 case reports
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41436-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Antineoplastics

Case report

Multiple drugs

Case report

Dinutuximab-beta